Wells Fargo analyst Mohit Bansal maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) on January 10 and set a price target ...
Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback